Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanda Castro-Borrero

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 29, 2023
Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis RegistryXiaotong Jiang, Gabrielle Simoneau, Mel Zuercher, et al.
Journal of Neurology|May 27, 2020
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension studyRalf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 31, 2023
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 studyBarry A Singer, Douglas L Arnold, Jelena Drulovic, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 29, 2023
Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis RegistryXiaotong Jiang, Gabrielle Simoneau, Mel Zuercher, et al.
Journal of Neurology|May 27, 2020
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension studyRalf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 31, 2023
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 studyBarry A Singer, Douglas L Arnold, Jelena Drulovic, et al.
Pageof 2